Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CytoVas, a diagnostics company in University of Pennsylvania’s UPStart incubator program in its Center for Technology Transfer has forged an alliance with a division of diagnostic company Becton Dickinson (NYSE: BDX) to advance a blood-based diagnostic to determine personal risk of cardiovascular disease and stroke. The alliance with Becton Bioscience will help CytoVas assess cardiovascular disease progression, as well as evaluate the side effects of existing and experimental medicines for cardiovascular disease. Last year CytoVas became the first company to get funding as part of the American Heart Association’s accelerator program, an initiative designed to speed up the investigation and development of products for cardiovascular disease patients. As of February it had begun to enroll patients in a proof of concept trial for its diagnostic to evaluate an individual’s vascular health profile. The test would be administered to patients being treated for cardiovascular disease, diabetes and cancer who may be symptom-free for cardiovascular disease and stroke but face an elevated risk for developing those condition.
Help employers find you! Check out all the jobs and post your resume.
